I-BET-762: A Potent BET Bromodomain Inhibitor for Inflammation and Cancer Research

Executive Summary: I-BET-762 (SKU B1498) is a highly potent and selective inhibitor of the BET (bromodomain and extra-terminal domain) protein family, with IC₅₀ values ranging from 32.5 to 42.5 nM and a K_d of 50.5–61.3 nM under in vitro assay conditions (APExBIO). It binds competitively to the acetyl-lysine binding pocket of BET proteins, displaying a unique 2:1 stoichiometry and minimal off-target activity against other bromodomain-containing proteins. I-BET-762 downregulates lipopolysaccharide (LPS)-inducible gene expression and reduces cytokine and chemokine production in preclinical inflammation models (Fan et al., 2024). It also enhances erastin-induced ferroptosis in multiple cancer cell lines by promoting reactive oxygen species (ROS) accumulation and FSP1 downregulation. The compound is supplied by APExBIO for research applications in epigenetic regulation, inflammatory disease modeling, and cancer biology.

Biological Rationale

The BET family (BRD2, BRD3, BRD4, BRDT) are chromatin readers that recognize acetyl-lysine residues on histones. These proteins regulate transcription of key genes involved in inflammation, proliferation, and oncogenesis (Fan et al., 2024). Aberrant BET activity is implicated in inflammatory diseases and cancer. Targeting BET bromodomains enables selective modulation of gene expression programs driving pathology. I-BET-762 is a benchmark BET inhibitor for dissecting these pathways (APExBIO).

Mechanism of Action of I-BET-762

I-BET-762 binds with high affinity to the acetyl-lysine (AcK) binding pockets of BET proteins, competitively displacing acetyl-lysine residues (APExBIO). Its structure allows a 2:1 binding ratio to BRD4, enhancing affinity and selectivity. I-BET-762 shows negligible interaction with other bromodomain-containing proteins under standard biochemical screening. Functionally, it downregulates LPS-induced gene expression in immune cells, resulting in reduced cytokine and chemokine release. In cancer models, I-BET-762 inhibits transcription of oncogenic drivers and promotes ferroptosis when combined with inducers like erastin (Fan et al., 2024).

Evidence & Benchmarks

• I-BET-762 inhibits BET bromodomains with IC₅₀ values of 32.5–42.5 nM, as established in biochemical assays (APExBIO).
• The compound competitively binds the AcK pocket of BET proteins with a K_d of 50.5–61.3 nM, as measured by isothermal titration calorimetry (ITC) (APExBIO).
• I-BET-762 displays a 2:1 binding stoichiometry to BET proteins, confirmed by structural studies (APExBIO).
• No significant binding to non-BET bromodomain proteins detected at up to 10 µM concentration (APExBIO).
• I-BET-762 downregulates LPS-induced expression of pro-inflammatory cytokines in murine models, leading to decreased levels of TNF-α and IL-6 in vivo (Fan et al., 2024, DOI).
• In HEK293T, HeLa, HepG2, RKO, and PC3 cell lines, I-BET-762 (2 µM) significantly enhances erastin-induced ferroptosis, as measured by propidium iodide staining and cell viability assays (Fan et al., 2024, DOI).
• Treatment with I-BET-762 leads to accumulation of reactive oxygen species (ROS) and downregulation of FSP1, a ferroptosis suppressor, in both HEK293T and HeLa cells (Fan et al., 2024, DOI).
• I-BET-762 is soluble at ≥21.19 mg/mL in DMSO and ≥13.93 mg/mL in ethanol (with sonication), but insoluble in water (APExBIO).
• Optimal storage is at -20°C as a solid; solutions should be used promptly to minimize degradation (APExBIO).

For deeper mechanistic perspectives, see I-BET-762: Integrating BET Inhibition with Ferroptosis Modulation, which focuses on the bridge between epigenetic control and ferroptosis, whereas this article provides updated quantitative benchmarks and workflow parameters.

Applications, Limits & Misconceptions

Research Applications:

• Epigenetic regulation and chromatin research
• Inflammatory disease models, including LPS-induced cytokine expression
• Cancer biology, especially in BET-dependent and FSP1-dependent cell lines
• Ferroptosis modulation in combination with inducers (e.g., erastin)
• BET protein signaling pathway dissection and transcriptional regulation studies

For translational and troubleshooting insights, compare with I-BET-762: A Selective BET Inhibitor Empowering Inflammation Research, which emphasizes practical workflows; here, we expand on mechanistic and quantitative evidence.

Common Pitfalls or Misconceptions

• I-BET-762 does not inhibit non-BET bromodomains at standard research concentrations (≤10 µM).
• The compound is not soluble in water; DMSO or ethanol (with sonication) is required for stock solutions.
• Prolonged storage of solutions at room temperature leads to degradation—use immediately after preparation.
• Effective only in systems with functional BET protein expression; not effective in BET knockout models.
• Enhancement of ferroptosis is context-dependent and may vary between cell types based on FSP1 status (Fan et al., 2024).

For further comparison across inflammation and epigenetic research, I-BET-762: Selective BET Inhibitor Transforming Inflammatory Disease Models focuses on workflows for inflammation, while this article prioritizes quantitative benchmarks and compound parameters.

Workflow Integration & Parameters

• Preparation: Dissolve I-BET-762 at ≥21.19 mg/mL in DMSO; for ethanol, use sonication to reach ≥13.93 mg/mL.
• Storage: Store solid at -20°C; avoid repeated freeze-thaw cycles.
• Working concentration: Typical in vitro assays use 1–2 µM; adjust based on sensitivity and cell type.
• Controls: Include DMSO-only control and, where relevant, BET knockout cells or negative selection with non-BET bromodomains.
• Combining agents: For ferroptosis studies, combine with erastin (20 µM) for 24–48 h; monitor ROS and FSP1 levels by appropriate assays (Fan et al., 2024).

Conclusion & Outlook

I-BET-762 is an established, highly selective BET bromodomain inhibitor with robust evidence supporting its role in epigenetic, inflammatory, and cancer biology research. Its high binding affinity, selectivity, and functional effects in transcriptional regulation and ferroptosis make it a standard tool for dissecting BET-mediated pathways. The compound's parameters, including solubility, storage, and concentration guidelines, are well-defined, supporting reproducibility. For authoritative product details and ordering, see the I-BET-762 product page at APExBIO. Ongoing research continues to clarify context-dependent effects, especially in ferroptosis and FSP1-dependent cancers.